MesenCure Archives - Amazing Health Advances

Israeli Covid Drug Also Aids Cancer Immunotherapy Patients

AHA Publisher — Wed, 18 May 2022 07:00:15 +0000

Diana Bletter via Israel21c – Israeli biotechnology company Bonus BioGroup announced that its Covid drug, MesenCure, can also reduce life-threatening inflammatory overreaction in cancer patients treated with immunotherapy. A trial conducted by Bonus BioGroup at the Jackson Laboratory in California showed that MesenCure significantly lowered the inflammatory overreaction in cancer patients that could have caused multisystem failure. Studies show that up to 27 percent of patients undergoing biological cancer treatment who suffer from inflammatory overreaction may develop this potentially fatal complication. Inflammatory overreaction develops in up to 78% of oncology patients treated with biological immunotherapies, which stimulate the immune system to fight cancer, as well as in patients transplanted with blood-forming stem cells. Experts estimate that by 2027, in the United States alone, more than 18,000 patients will suffer from an inflammatory overreaction following biological treatments for cancer that could subsequently develop into a fatal condition. Shai Meretzki, CEO of Bonus BioGroup, said the company’s focus from the start has been cell therapy and tissue engineering to achieve bone tissue regeneration and reconstruction. The main building block is mesenchymal cells extracted from the patient’s adipose tissue. With the outbreak of the global coronavirus epidemic, Bonus BioGroup started experimenting with the very same mesenchymal cells, isolated from adipose tissue of healthy donors, to enhance ability to reduce inflammatory processes, including respiratory infections and other diseases. These efforts led to MesenCure, which Bonus BioGroup will continue to develop to treat severely ill Covid patients. “Demonstrating the success of the drug product MesenCure to integrate with cancer therapies is an important milestone for the company in realizing its vision to become a world leader in cellular therapy for the treatment of various diseases and medical conditions. These indications will present further financial opportunities … and will position Bonus BioGroup as an essential player in the field of oncology, in addition to regenerative medicine and tissue engineering,” Meretzki said. To read the original article click here.

The post Israeli Covid Drug Also Aids Cancer Immunotherapy Patients appeared first on Amazing Health Advances.

Drug Saves 47 of 50 Severe Covid Patients in Trial

AHA Publisher — Mon, 29 Nov 2021 08:23:27 +0000

Abigail Klein Leichman via Israel21c – Israel’s Bonus BioGroup reports a survival rate of 94 percent (47 of 50) of the severe Covid-19 patients treated with its drug product MesenCure in a Phase II, multicenter clinical trial. Study results, soon to be published, show MesenCure treatment reduced study participants’ hospitalization period by about half compared to a control group. All these patients had life-threatening pneumonia and respiratory distress caused by Covid-19. The data shows that MesenCure treatment reduced mortality by about 70% compared with the control group. Only two of the first 30 severe Covid-19 patients treated with MesenCure died due to Covid-19 or its complications, while 14 of 60 similar patients in the control group died. MesenCure treatment shortened the hospitalization period of severe Covid-19 patients by eight days on average, a reduction of 45% relative to the control group. The experimental group included women and men aged 41.4 to 77.4. About 77% of the severe Covid-19 patients treated in three hospitals with MesenCure had one or more risk factors for poor prognosis: hypertension, hyperlipidemia, obesity and Type 2 diabetes. Most were treated during the fourth Covid-19 wave in Israel, dominated by the Delta strain. The control group received the current standard of care — anti-inflammatory drugs in combination with steroids. This regimen, according to Bonus BioGroup, reduces mortality in hospitalized Covid-19 patients only slightly, from 25.8% to 21.8%, indicating that MesenCure is four times more effective. “We are proud of our success in leading the world to be a safer place by developing a medication for severe Covid-19 patients, thereby dramatically reducing the threat to their lives,” said Dr. Shai Meretzki, CEO of Bonus BioGroup. “In less than two years from the epidemic outbreak, we are the first in the world to report an effective and significant treatment for severely ill patients.” According to a statement from Bonus BioGroup, an independent expert committee confirmed the findings of the Phase II clinical trial of MesenCure and recommended continuing toward Phase III. Meretzki told the Jerusalem Post that the company will apply for emergency use approval from European and US regulatory agencies. To read the original article click here.

The post Drug Saves 47 of 50 Severe Covid Patients in Trial appeared first on Amazing Health Advances.